Tuberculosis treatment
I'll start by reading the medical library skill, then search for tuberculosis treatment content in parallel.
Reading File
Now I'll search the medical library and PubMed in parallel for comprehensive TB treatment coverage.
Finding Sources
Searching PubMed
"tuberculosis"[MeSH Terms] AND "drug therapy"[MeSH Terms]
Good results. Now I'll read the key textbook sections in parallel - the most comprehensive sources on TB treatment.
Reading File
Reading File
Reading File
Excellent data. Let me now read the latent TB treatment section and drug-resistant TB sections from Murray & Nadel, and more of the Tintinalli section.
Reading File
Reading File
Finding Sources
Now let me read Harrison's section on first-line drugs and the Murray & Nadel drug-resistant TB section:
Reading File
Reading File
I now have rich data to compose a comprehensive answer. Let me compile everything into a structured response.
Tuberculosis Treatment
Overview
TB treatment requires combination drug therapy because monotherapy rapidly selects resistant mutants. The regimen is divided into two phases: an intensive phase that kills actively dividing bacilli, and a continuation phase that eliminates persistent organisms and prevents relapse. - Murray & Nadel's Textbook of Respiratory Medicine
1. Drug-Susceptible Pulmonary TB
Standard 6-Month Regimen (Preferred)
Intensive Phase (8 weeks): HRZE
- Isoniazid (INH) 300 mg/day
- Rifampin (RIF) 600 mg/day
- Pyrazinamide (PZA) 15-30 mg/kg/day
- Ethambutol (EMB) 15-20 mg/kg/day
Continuation Phase (18 weeks): INH + RIF daily (or INH + rifapentine)
This regimen achieves cure in >95% of drug-susceptible cases when completed. - Tintinalli's Emergency Medicine
Newer 4-Month Regimen (HRZE + Moxifloxacin)
Shown non-inferior to the standard 6-month regimen for drug-susceptible pulmonary TB in persons ≥12 years weighing ≥40 kg:
| Phase | Drugs | Duration |
|---|---|---|
| Intensive | Rifapentine + Moxifloxacin + INH + PZA | 8 weeks daily |
| Continuation | Rifapentine + Moxifloxacin + INH | 9 weeks daily |
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Dosing Options
| Drug | Daily | 3x/week DOT | 2x/week DOT |
|---|---|---|---|
| Isoniazid | 5 mg/kg (max 300 mg) | 15 mg/kg (max 900 mg) | 15 mg/kg (max 900 mg) |
| Rifampin | 10 mg/kg (max 600 mg) | 10 mg/kg (max 600 mg) | 10 mg/kg (max 600 mg) |
| Ethambutol | 15-20 mg/kg (max 1.6 g) | 25-30 mg/kg | 50 mg/kg |
| Pyrazinamide | 15-30 mg/kg (max 2 g) | 50 mg/kg (max 3 g) | 50 mg/kg (max 2 g) |
- Tintinalli's Emergency Medicine, Table 67-3
2. Directly Observed Therapy (DOT)
DOT is strongly recommended by the CDC, especially for:
- All twice-weekly or thrice-weekly regimens (mandatory DOT)
- Patients with compliance concerns
- Drug-resistant TB cases
DOT significantly reduces relapse and secondary resistance development. - Tintinalli's Emergency Medicine
3. Extended Treatment Indications
Prolonged therapy (up to 9 months total) is used for:
- Immunocompromised patients (HIV, transplant, steroids)
- Cavitary pulmonary TB with positive sputum culture after 2 months
- Extrapulmonary TB: disseminated, CNS, skeletal
- Drug-resistant TB
4. Key Drug Mechanisms & Adverse Effects
| Drug | Mechanism | Key Adverse Effects |
|---|---|---|
| Isoniazid | Prodrug activated by KatG; inhibits mycolic acid synthesis (InhA) | Hepatitis (5-33%), peripheral neuropathy - give pyridoxine 25-50 mg/day |
| Rifampin | Inhibits bacterial RNA polymerase | Hepatitis, thrombocytopenia, GI disturbance, strong CYP inducer (many drug interactions) |
| Pyrazinamide | Bactericidal in acidic environment (within macrophages) | Hepatitis, arthralgia, hyperuricemia |
| Ethambutol | Inhibits arabinosyl transferase (cell wall synthesis) | Retrobulbar/optic neuritis (dose-related), peripheral neuropathy |
| Rifapentine | Same as rifampin (long-acting) | Hepatitis, thrombocytopenia, porphyria exacerbation |
Monitor LFTs if: preexisting liver disease, alcohol use, pregnancy, HIV, hepatitis C. Stop anti-TB medications if AST >5x ULN or bilirubin >3 mg/dL. - Harrison's Principles of Internal Medicine 22E
5. Drug-Resistant TB
Definitions
- MDR-TB: Resistant to at least INH + rifampin
- XDR-TB: MDR-TB + resistant to a fluoroquinolone + at least one injectable second-line drug
BPaLM Regimen (WHO, 2022 - now preferred for MDR/XDR-TB)
- Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
- 6-month all-oral regimen
- Recent meta-analyses (2025) confirm bedaquiline + linezolid-based regimens achieve high treatment success for MDR-TB
Second-Line Drugs (for DR-TB)
| Drug | Typical Adult Dose |
|---|---|
| Bedaquiline | 400 mg/day (first 2 wks), then 200 mg 3x/wk |
| Pretomanid | 200 mg/day |
| Linezolid | 600 mg/day |
| Moxifloxacin | 400 mg/day |
| Levofloxacin | 750-1000 mg/day |
| Amikacin | 15 mg/kg/day (injectable) |
| Cycloserine | 500-1000 mg/day divided |
| Ethionamide | 500-750 mg/day |
| Rifabutin | 300 mg/day (used when rifampin not tolerated) |
| Aminosalicylic acid | 8-12 g/day |
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Risk factors for drug resistance: prior TB treatment, residence in high-prevalence area, known MDR-TB contact. - Tintinalli's Emergency Medicine
6. Latent TB Infection (LTBI) Treatment
| Regimen | Duration | Frequency | Notes |
|---|---|---|---|
| INH alone | 9 months (preferred) | Daily or twice-weekly | 70% reduction in reactivation risk |
| INH alone | 6 months | Daily | Not for HIV, children, or fibrotic lesions |
| Rifampin | 4 months | Daily | Good alternative to INH |
| INH + Rifapentine (3HP) | 3 months | Once weekly | Preferred short-course; DOT or self-administered |
| INH + Rifapentine (1HP) | 1 month | Daily | HIV-infected adults ≥13 years |
Shorter rifamycin-based regimens are preferred to improve adherence. Nine months of daily INH is preferred in pregnant women at high risk for progression. - Murray & Nadel's Textbook of Respiratory Medicine
Treatment for LTBI reduces reactivation risk by approximately 70%. Before starting, always exclude active TB with history, exam, chest X-ray, and sputum testing if indicated. - Tintinalli's Emergency Medicine
7. Special Populations
| Population | Key Considerations |
|---|---|
| HIV co-infection | Start ART; manage rifampin drug interactions; use lower TST cut-points; consider empiric LTBI treatment even with negative IGRA if CD4 <200 |
| Pregnancy | Avoid PZA in some guidelines (1st trimester); 9-month INH preferred for LTBI in high-risk pregnant women; avoid streptomycin (ototoxicity to fetus) |
| Children | Weight-based dosing; 3HP regimen approved ≥2 years; 1HP not recommended <2 years |
| Liver disease | Monitor LFTs closely; may need to modify or substitute hepatotoxic agents |
| CNS/miliary TB | Extend treatment to 9-12 months; add corticosteroids for TB meningitis |
8. Immune Reconstitution Inflammatory Syndrome (IRIS)
In HIV+ patients starting both ART and TB treatment, paradoxical IRIS may develop - worsening symptoms (fever, lymphadenopathy, pulmonary infiltrates, hypercalcemia) due to immune recovery. Distinguish from treatment failure or resistance by clinical context and drug susceptibility testing. - Tintinalli's Emergency Medicine
Recent Evidence (2025)
Two recent meta-analyses support the current trend toward all-oral bedaquiline-based shorter regimens for drug-resistant TB:
- Bedaquiline + linezolid meta-analysis (PMID 40172415) - confirms efficacy of this combination for MDR-TB
- All-oral bedaquiline shorter regimens meta-analysis (PMID 40194835) - demonstrates high treatment success rates, supporting global shift away from injectables
These findings align with WHO 2022 consolidated guidelines, which now prioritize all-oral regimens and have moved injectables to Group C (used only when others cannot be composed).
This is a shared conversation. Sign in to Orris to start your own chat.